Generating lung-metastatic osteosarcoma targeting aptamers for in vivo and clinical tissue imaging.
Osteosarcoma (OS) is one of most malignant bone tumors in early adolescence, which is a highly metastatic cancer and pulmonary metastasis is the most common cause of death. Thus, the development of efficient approaches to discover potential compounds that target metastasis of OS remains a topic of considerable interest. In this study, subtractive Cell-SELEX was performed to screen OS metastasis specific DNA aptamers by using cell lines with similar tumorigenic potentials but opposite metastatic aggressiveness (highly metastatic 143B cells and non-metastatic U-2 OS cells as the target and negative cells, respectively). This in vitro selection generated an ssDNA aptamer LP-16 that exhibited high binding affinity to 143B cells with an equilibrium dissociation constant (Kd) of 56.73 ± 7.750 nM. However, the aptamer LP-16 did not bind to the non-metastatic U-2 OS and normal hFOB 1.19 cells. We further preliminarily presumed the target molecules of aptamer LP-16 was a membrane protein on the cell surface by proteinase treatment. Furthermore, both in vivo fluorescence imaging and clinical tissue imaging also clearly demonstrated that LP-16 could achieve prominently targeting efficiency. Therefore, the ssDNA aptamer LP-16 generated here could be a promising molecular probe for OS metastasis diagnosis. We have developed subtractive Cell-SELEX to screen osteosarcoma metastasis specific DNA aptamers by using cell lines with similar tumorigenic potentials but opposite metastatic aggressiveness (highly metastatic 143B cells and non-metastatic U-2 OS cells as the target and negative cells, respectively).